Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma

详细信息    查看全文

• 作者：Kimmen Quan ; MD ; FRCPC ; Karen M. Xu ; BS ; Yongqian Zhang ; PhD ; David A. Clump ; MD ; PhD ; John C. Flickinger ; MD ; Ron Lalonde ; PhD ; Steven A. Burton ; MD ; Dwight E. Heron ; MD ; MBA ; FACRO ; FACR ; ^{herond2@upmc.edu" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Seminars in Radiation Oncology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：26
• 期：2
• 页码：112-119
• 全文大小：348 K

文摘

Stereotactic ablative radiotherapy (SABR) with concomitant cetuximab is an effective treatment option for previously irradiated, locally recurrent squamous cell carcinoma of the head and neck. Its local control and overall survival are similar to those of other available treatment options. Each retreatment depends heavily on the prior treatment and every patient is a special case. Based on the experience of our institution and previously published studies, for patients who receive concomitant cetuximab with a median prior radiation therapy dose of 70 Gy, we recommend a total dose of 40-44 Gy delivered in 5 fractions on alternating days over 1-2 weeks. However, Grade 2 or 3 toxicities are not uncommon. Therefore, in this review, we also report a pilot study that applies a normal tissue complication probability dose-response model to estimate the probability of toxicities in locally recurrent squamous cell carcinoma of the head and neck reirradiated with SABR. Although this dose-response model includes concurrent targeted therapy and no comparable model yet exists for SABR without it, complication rates without concurrent biological therapy or chemotherapy should be no higher than those described here.